The University of Chicago Header Logo

Connection

George Bakris to Kidney Diseases

Back to Details
This is a "connection" page, showing publications George Bakris has written about Kidney Diseases.
George Bakris
Connection Strength
18.667
Kidney Diseases
  1. Initial Drops in Glomerular Filtration Rate with Certain Drug Classes Retard Kidney Disease Progression. Am J Nephrol. 2022; 53(7):513-515.
    View in: PubMed
    Score: 0.649
  2. Heart Failure and Changes in Kidney Function: Focus on Understanding, Not Reacting. Heart Fail Clin. 2019 Oct; 15(4):455-461.
    View in: PubMed
    Score: 0.531
  3. Blood Pressure Control and Cardiovascular/Renal Outcomes. Endocrinol Metab Clin North Am. 2018 03; 47(1):175-184.
    View in: PubMed
    Score: 0.482
  4. The role of aldosterone in the spectrum of cardiovascular and kidney disease risk: introduction. Semin Nephrol. 2014 May; 34(3):245-6.
    View in: PubMed
    Score: 0.369
  5. Renin inhibition in patients with chronic kidney disease: is it conclusively non-indicated? J Renin Angiotensin Aldosterone Syst. 2014 Mar; 15(1):97-8.
    View in: PubMed
    Score: 0.365
  6. Kidney dysfunction, cardiorespiratory fitness, and the risk of death in women. J Womens Health (Larchmt). 2012 Sep; 21(9):917-24.
    View in: PubMed
    Score: 0.320
  7. Blood pressure targets for patients with diabetes or kidney disease. Curr Hypertens Rep. 2011 Dec; 13(6):452-5.
    View in: PubMed
    Score: 0.313
  8. Renal function and target organ damage in hypertension. Eur Heart J. 2011 Jul; 32(13):1599-604.
    View in: PubMed
    Score: 0.298
  9. Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab. 2010 Dec; 12(12):1079-83.
    View in: PubMed
    Score: 0.292
  10. Fixed-dose combination and chronic kidney disease progression: which is the best? Curr Opin Nephrol Hypertens. 2010 Sep; 19(5):450-5.
    View in: PubMed
    Score: 0.287
  11. Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother. 2010 Nov; 11(16):2675-86.
    View in: PubMed
    Score: 0.286
  12. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int. 2010 Oct; 78(8):726-36.
    View in: PubMed
    Score: 0.286
  13. Dual RAAS blockade is desirable in kidney disease: con. Kidney Int. 2010 Sep; 78(6):546-9.
    View in: PubMed
    Score: 0.285
  14. More complete renin-angiotensin system blockade: better outcomes or smoke and mirrors. J Hypertens. 2010 Jul; 28(7):1382-3.
    View in: PubMed
    Score: 0.283
  15. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol. 2010; 31(5):469-70.
    View in: PubMed
    Score: 0.280
  16. National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2009: executive summary. Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S1-3.
    View in: PubMed
    Score: 0.277
  17. Pediatrics: blood pressure target for renoprotection in children. Nat Rev Nephrol. 2010 Feb; 6(2):67-8.
    View in: PubMed
    Score: 0.275
  18. Kidney early evaluation program: a community-based screening approach to address disparities in chronic kidney disease. Semin Nephrol. 2010 Jan; 30(1):66-73.
    View in: PubMed
    Score: 0.274
  19. Prehypertension: is it relevant for nephrologists? Kidney Int. 2010 Feb; 77(3):194-200.
    View in: PubMed
    Score: 0.272
  20. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Curr Opin Nephrol Hypertens. 2009 Sep; 18(5):386-91.
    View in: PubMed
    Score: 0.268
  21. Lower blood pressure goals for cardiovascular and renal risk reduction: are they defensible? J Clin Hypertens (Greenwich). 2009 Jul; 11(7):345-7.
    View in: PubMed
    Score: 0.264
  22. Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians. Postgrad Med. 2009 Jul; 121(4):51-60.
    View in: PubMed
    Score: 0.264
  23. Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons? Ann Intern Med. 2009 May 19; 150(10):731-3.
    View in: PubMed
    Score: 0.262
  24. Hypertension: the message of World Kidney Day 2009. Nat Rev Nephrol. 2009 Apr; 5(4):188-90.
    View in: PubMed
    Score: 0.260
  25. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Kidney Int. 2009 Mar; 75(5):449-52.
    View in: PubMed
    Score: 0.258
  26. The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. Nephrol Dial Transplant. 2009 Mar; 24(3):695-7.
    View in: PubMed
    Score: 0.258
  27. World Kidney Day 2009: hypertension and kidney disease is a marriage that should be prevented. Am J Kidney Dis. 2009 Mar; 53(3):373-6.
    View in: PubMed
    Score: 0.258
  28. The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented. Clin Nephrol. 2009 Mar; 71(3):239-43.
    View in: PubMed
    Score: 0.258
  29. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. J Clin Hypertens (Greenwich). 2009 Mar; 11(3):144-7.
    View in: PubMed
    Score: 0.258
  30. The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. Kidney Blood Press Res. 2009; 32(1):67-70.
    View in: PubMed
    Score: 0.258
  31. The message for World Kidney Day 2009. Hypertension and kidney disease: a marriage that should be prevented. Nephron Clin Pract. 2009; 111(2):c155-8.
    View in: PubMed
    Score: 0.258
  32. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Am J Nephrol. 2009; 30(1):95-8.
    View in: PubMed
    Score: 0.258
  33. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Clin J Am Soc Nephrol. 2009 Mar; 4(3):517-9.
    View in: PubMed
    Score: 0.258
  34. The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. Nephrology (Carlton). 2009 Feb; 14(1):49-51.
    View in: PubMed
    Score: 0.257
  35. The message for World Kidney Day 2009: hypertension and kidney disease-a marriage that should be prevented. Clin Exp Nephrol. 2009 Feb; 13(1):96-9.
    View in: PubMed
    Score: 0.257
  36. The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented. J Hum Hypertens. 2009 Mar; 23(3):222-5.
    View in: PubMed
    Score: 0.257
  37. The message for World Kidney Day 2009: hypertension and kidney disease-a marriage that should be prevented. Pediatr Nephrol. 2009 Mar; 24(3):427-30.
    View in: PubMed
    Score: 0.256
  38. The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. Arch Iran Med. 2009 Jan; 12(1):102-5.
    View in: PubMed
    Score: 0.256
  39. The message for World Kidney Day 2009: hypertension and kidney disease, a marriage that should be prevented. Iran J Kidney Dis. 2009 Jan; 3(1):7-10.
    View in: PubMed
    Score: 0.256
  40. Should nephrologists use beta-blockers? A perspective. Nephrol Dial Transplant. 2009 Mar; 24(3):701-2.
    View in: PubMed
    Score: 0.254
  41. Renal hemodynamic changes in heart failure. Heart Fail Clin. 2008 Oct; 4(4):411-23.
    View in: PubMed
    Score: 0.251
  42. Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade. Heart Fail Clin. 2008 Oct; 4(4):425-38.
    View in: PubMed
    Score: 0.251
  43. Calcium antagonists: Do they equally protect against kidney injury? Kidney Int. 2008 Apr; 73(7):795-6.
    View in: PubMed
    Score: 0.243
  44. Executive summary: Kidney Early Evaluation Program (KEEP) 2007 Annual Data Report. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S1-2.
    View in: PubMed
    Score: 0.243
  45. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S30-7.
    View in: PubMed
    Score: 0.243
  46. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol. 2008 Jan; 3 Suppl 1:S3-10.
    View in: PubMed
    Score: 0.238
  47. ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression? J Clin Hypertens (Greenwich). 2007 Jun; 9(6):413-5.
    View in: PubMed
    Score: 0.229
  48. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol. 2006 Mar; 1(2):229-35.
    View in: PubMed
    Score: 0.206
  49. Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension. 2005 Oct; 46(4):637-42.
    View in: PubMed
    Score: 0.203
  50. Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study. Am J Nephrol. 2005 Jul-Aug; 25(4):393-9.
    View in: PubMed
    Score: 0.201
  51. Preventing hypertensive kidney disease: the critical role of combination therapy. Am J Hypertens. 2005 Apr; 18(4 Pt 2):93S-94S.
    View in: PubMed
    Score: 0.197
  52. Protecting renal function in the hypertensive patient: clinical guidelines. Am J Hypertens. 2005 Apr; 18(4 Pt 2):112S-119S.
    View in: PubMed
    Score: 0.197
  53. Implications of albuminuria on kidney disease progression. J Clin Hypertens (Greenwich). 2004 Nov; 6(11 Suppl 3):18-22.
    View in: PubMed
    Score: 0.191
  54. The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2004 Mar; 13(2):155-61.
    View in: PubMed
    Score: 0.183
  55. Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans. Curr Opin Nephrol Hypertens. 2003 Jan; 12(1):79-84.
    View in: PubMed
    Score: 0.169
  56. Treatment of hypertension in patients with renal disease. Cardiovasc Drugs Ther. 2002 Dec; 16(6):503-10.
    View in: PubMed
    Score: 0.168
  57. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Clin J Am Soc Nephrol. 2021 03 08; 16(3):384-395.
    View in: PubMed
    Score: 0.148
  58. Major adverse renal events (MARE): a proposal to unify renal endpoints. Nephrol Dial Transplant. 2021 02 20; 36(3):491-497.
    View in: PubMed
    Score: 0.148
  59. Treatment of stage I hypertension and development of renal dysfunction. J Hum Hypertens. 2001 Feb; 15(2):81-4.
    View in: PubMed
    Score: 0.148
  60. Evolution of drugs that preserve renal function. J Clin Pharmacol. 2000 Sep; 40(9):978-89.
    View in: PubMed
    Score: 0.143
  61. The future of clinical trials in chronic renal disease: outcome of an NIH/FDA/Physician Specialist Conference. Evaluation of Clinical Trial Endpoints in Chronic Renal Disease Study Group. J Clin Pharmacol. 2000 Aug; 40(8):815-25.
    View in: PubMed
    Score: 0.143
  62. Oral antidiabetic agents safe with renal disease? Postgrad Med. 2000 Jun; 107(7):66.
    View in: PubMed
    Score: 0.141
  63. Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. Diabetes Obes Metab. 2020 05; 22(5):798-806.
    View in: PubMed
    Score: 0.138
  64. "Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives". J Clin Pharmacol. 2000 Jan; 40(1):7-10.
    View in: PubMed
    Score: 0.137
  65. The role of combination antihypertensive therapy and the progression of renal disease hypertension: looking toward the next millennium. Am J Hypertens. 1998 Oct; 11(10):158S-162S.
    View in: PubMed
    Score: 0.126
  66. Angiotensin II receptor blockers in hypertension and renal disease. Hosp Pract (1995). 1998 Apr 15; 33(4):19-22.
    View in: PubMed
    Score: 0.122
  67. Angiotensin II receptor blockade and progression of nondiabetic-mediated renal disease. Kidney Int Suppl. 1997 Dec; 63:S67-70.
    View in: PubMed
    Score: 0.119
  68. Microalbuminuria and progressive renal disease. J Hum Hypertens. 1994 Nov; 8(11):809-17.
    View in: PubMed
    Score: 0.096
  69. Renal adaptation to the failing heart. Understanding the cascade of responses. Postgrad Med. 1994 Jun; 95(8):141-6, 149-50.
    View in: PubMed
    Score: 0.093
  70. Renal adaptation to the failing heart. Avoiding a 'therapeutic misadventure'. Postgrad Med. 1994 Jun; 95(8):153-6.
    View in: PubMed
    Score: 0.093
  71. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014; 37(3):867-75.
    View in: PubMed
    Score: 0.090
  72. Recognition and management of masked hypertension: a review and novel approach. J Am Soc Hypertens. 2013 May-Jun; 7(3):244-52.
    View in: PubMed
    Score: 0.086
  73. Lipid disorders in uremia and dialysis. Contrib Nephrol. 2012; 178:100-105.
    View in: PubMed
    Score: 0.081
  74. Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes. Curr Vasc Pharmacol. 2012 Mar; 10(2):156-61.
    View in: PubMed
    Score: 0.080
  75. The United Nations high level meeting addresses noncommunicable diseases, but where is hypertension? J Clin Hypertens (Greenwich). 2011 Nov; 13(11):787-90.
    View in: PubMed
    Score: 0.077
  76. National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2010: executive summary. Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S1-3.
    View in: PubMed
    Score: 0.074
  77. Do fibrates truly preserve kidney function? Nat Rev Endocrinol. 2011 Mar; 7(3):130-1.
    View in: PubMed
    Score: 0.074
  78. Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S4-S14.
    View in: PubMed
    Score: 0.069
  79. Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol. 2010 Jan 04; 105(1 Suppl):21A-9A.
    View in: PubMed
    Score: 0.069
  80. Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation Program. J Clin Hypertens (Greenwich). 2010 Jan; 12(1):51-8.
    View in: PubMed
    Score: 0.068
  81. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol. 2010; 31(2):95-103.
    View in: PubMed
    Score: 0.068
  82. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S46-55.
    View in: PubMed
    Score: 0.061
  83. N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK). Circulation. 2008 Apr 01; 117(13):1685-92.
    View in: PubMed
    Score: 0.061
  84. Low birth weight is associated with chronic kidney disease only in men. Kidney Int. 2008 Mar; 73(5):637-42.
    View in: PubMed
    Score: 0.059
  85. A comparative evaluation of various methods for microalbuminuria screening. Am J Nephrol. 2008; 28(2):324-9.
    View in: PubMed
    Score: 0.059
  86. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007 Jun 11; 167(11):1122-9.
    View in: PubMed
    Score: 0.057
  87. The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension. Blood Press. 2007; 16(2):72-9.
    View in: PubMed
    Score: 0.056
  88. Does dietary salt increase the risk for progression of kidney disease? Curr Hypertens Rep. 2005 Oct; 7(5):385-91.
    View in: PubMed
    Score: 0.051
  89. Is proteinuria a plausible target of therapy? Curr Hypertens Rep. 2004 Jun; 6(3):177-81.
    View in: PubMed
    Score: 0.046
  90. The importance of blood pressure control in the patient with diabetes. Am J Med. 2004 Mar 08; 116 Suppl 5A:30S-38S.
    View in: PubMed
    Score: 0.046
  91. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003 Oct; 42(4):617-22.
    View in: PubMed
    Score: 0.044
  92. Evaluation and treatment of patients with systemic hypertension. Circulation. 2002 May 28; 105(21):2458-61.
    View in: PubMed
    Score: 0.040
  93. Microalbuminuria: what is it? Why is it important? What should be done about it? J Clin Hypertens (Greenwich). 2001 Mar-Apr; 3(2):99-102.
    View in: PubMed
    Score: 0.037
  94. Lithium prophylaxis and the kidney. J Affect Disord. 1981 Mar; 3(1):37-42.
    View in: PubMed
    Score: 0.037
  95. Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens. 1996 May; 5(3):219-23.
    View in: PubMed
    Score: 0.027
  96. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012 Nov; 33(22):2782-95.
    View in: PubMed
    Score: 0.021
  97. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011 Jul-Aug; 5(4):259-352.
    View in: PubMed
    Score: 0.019
  98. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S9-16.
    View in: PubMed
    Score: 0.019
  99. Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study. J Am Soc Hypertens. 2010 Jan-Feb; 4(1):22-31.
    View in: PubMed
    Score: 0.017
  100. Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome. Postgrad Med. 2002 Oct; 112(4):24-6, 29-30, 33-4 passim.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.